JNJ|Johnson & Johnson|Price:229.320|Chg%:-0.68

More Details of Johnson & Johnson Company

Johnson & Johnson is an American multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange (NYSE:JNJ). Its common stock is part of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest corporations in the United States. In 2024, it was ranked 45th on the Forbes Global 2000 list. Johnson & Johnson employs approximately 138,000 individuals globally, led by its current chairman and CEO, Joaquin Duato.

Founded in 1886 by three brothers—Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson—the company initially focused on selling ready-to-use sterile surgical dressings. In 2023, the firm spun off its consumer healthcare business segment into a new publicly traded entity, Kenvue, allowing it to concentrate solely on the development and manufacturing of pharmaceutical prescription drugs and medical device technologies.

Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.

Johnson & Johnson Info



Ticker SymbolJNJ

Company nameJohnson & Johnson

IPO dateOct 31, 2080

CEODuato (Joaquin Boix)

Number of employees138100

Security typeOrdinary Share

Fiscal year-endOct 31

AddressOne Johnson & Johnson Plaza

CityNEW BRUNSWICK

Stock exchangeNASDAQ OMX NASDAQ Basic NYSE

CountryUnited States of America

Postal code08933

Phone17325242455

Websitehttps://www.jnj.com/

Ticker SymbolJNJ

IPO dateOct 31, 2080

CEODuato (Joaquin Boix)

Company Executives of Johnson & Johnson



Name

Name/Position

Position

Shareholding

Change

Mr. Joaquin Boix Duato

Chairman of the Board, Chief Executive Officer

356.30K

+22.28%

Ms. Jennifer L. Taubert

Executive Vice President, Worldwide Chairman, Innovative Medicine

194.45K

+8.45%

Ms. Kathryn E. Wengel

Executive Vice President, Chief Technology Officer and Risk Officer

114.63K

+17.45%

Mr. Joseph J. Wolk

Chief Financial Officer, Executive Vice President

85.01K

+0.07%

Prof. Dr. John C. Reed, M.D., Ph.D.

Executive Vice President - Innovative Medicine, Research and Development

24.91K

+57.22%

Ms. Elizabeth (Liz) Forminard

Executive Vice President, Chief Legal Officer

23.57K

+45.46%

Ms. Vanessa Broadhurst

Executive Vice President - Global Corporate Affairs

23.00K

-2.57%

Ms. Kristen Mulholland

Chief Human Resources Officer, Executive Vice President

19.83K

+28.80%

Mr. Hubert Joly

Independent Director

5.00K

--

Ms. Marillyn A. Hewson

Lead Independent Director

3.00K

--

Name

Name/Position

Position

Shareholding

Change

Mr. Joaquin Boix Duato

Chairman of the Board, Chief Executive Officer

356.30K

+22.28%

Ms. Jennifer L. Taubert

Executive Vice President, Worldwide Chairman, Innovative Medicine

194.45K

+8.45%

Ms. Kathryn E. Wengel

Executive Vice President, Chief Technology Officer and Risk Officer

114.63K

+17.45%

Mr. Joseph J. Wolk

Chief Financial Officer, Executive Vice President

85.01K

+0.07%

Prof. Dr. John C. Reed, M.D., Ph.D.

Executive Vice President - Innovative Medicine, Research and Development

24.91K

+57.22%

Ms. Elizabeth (Liz) Forminard

Executive Vice President, Chief Legal Officer

23.57K

+45.46%

Revenue Breakdown

Currency: USDUpdated: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Oncology-DARZALEX

14.35B

15.24%

Immunology-STELARA

6.08B

6.45%

Cardiovascular-ELECTROPHYSIOLOGY

5.63B

5.98%

Surgery-General

5.56B

5.90%

Immunology-TREMFYA

5.16B

5.47%

Other

57.41B

60.95%

By RegionUSD

Name

Revenue

Proportion

United States

53.75B

57.07%

International

40.44B

42.93%

Europe

21.54B

22.86%

Asia-Pacific, Africa

14.03B

14.90%

Western Hemisphere, excluding U.S.

4.88B

5.18%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Oncology-DARZALEX

14.35B

15.24%

Immunology-STELARA

6.08B

6.45%

Cardiovascular-ELECTROPHYSIOLOGY

5.63B

5.98%

Surgery-General

5.56B

5.90%

Immunology-TREMFYA

5.16B

5.47%

Other

57.41B

60.95%

Shareholding Stats

Updated: Sun, May 10

Shareholders

Shareholder Types

Shareholders

Proportion

Vanguard Capital Management, LLC

6.51%

State Street Investment Management (US)

5.56%

BlackRock Institutional Trust Company, N.A.

5.44%

Vanguard Portfolio Management, LLC

2.64%

Geode Capital Management, L.L.C.

2.41%

Other

77.45%

Shareholders

Proportion

Vanguard Capital Management, LLC

6.51%

State Street Investment Management (US)

5.56%

BlackRock Institutional Trust Company, N.A.

5.44%

Vanguard Portfolio Management, LLC

2.64%

Geode Capital Management, L.L.C.

2.41%

Other

77.45%

Shareholder Types

Shareholders

Proportion

Investment Advisor

40.66%

Investment Advisor/Hedge Fund

23.83%

Research Firm

3.28%

Pension Fund

2.20%

Bank and Trust

2.14%

Insurance Company

1.62%

Sovereign Wealth Fund

1.48%

Hedge Fund

0.61%

Family Office

0.08%

Other

24.12%

Institutional Shareholding



Updated: Sun, Apr 5

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q1

6338

1.78B

73.80%

-65.47M

2025Q4

6038

1.81B

75.24%

+5.09M

2025Q3

5885

1.79B

74.44%

+16.50K

2025Q2

5920

1.78B

73.89%

-7.65M

2025Q1

6002

1.80B

74.62%

+4.60M

2024Q4

5953

1.78B

74.14%

+8.28M

2024Q3

5699

1.77B

73.47%

+2.69M

2024Q2

5691

1.75B

72.75%

+9.12M

2024Q1

5685

1.73B

71.58%

-6.08M

2023Q4

5686

1.72B

71.40%

-7.80M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

State Street Investment Management (US)

133.87M

5.56%

+1.66M

+1.26%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

130.93M

5.44%

+1.51M

+1.17%

Dec 31, 2025

Geode Capital Management, L.L.C.

57.95M

2.41%

+1.74M

+3.09%

Dec 31, 2025

JP Morgan Asset Management

39.68M

1.65%

+3.08M

+8.41%

Dec 31, 2025

State Farm Insurance Companies

34.11M

1.42%

--

Dec 31, 2025

Norges Bank Investment Management (NBIM)

33.46M

1.39%

+1.53M

+4.79%

Dec 31, 2025

Morgan Stanley Smith Barney LLC

23.96M

0.99%

-1.30M

-5.14%

Dec 31, 2025

Wellington Management Company, LLP

23.24M

0.96%

-2.59M

-10.04%

Dec 31, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

iShares U.S. Pharmaceuticals ETF

23.7%

VanEck Pharmaceutical ETF

10.06%

FT Vest DJIA Dogs 10 Target Income ETF

9.82%

Health Care Select Sector SPDR Fund

9.32%

Proshares Ultra Health Care

9%

iShares U.S. Healthcare ETF

8.9%

JPMorgan Healthcare Leaders ETF

8.38%

First Trust NASDAQ Pharmaceuticals ETF

8.28%

Fidelity MSCI Health Care Index ETF

7.67%

Franklin Income Focus ETF

7.08%

iShares U.S. Pharmaceuticals ETF

Proportion23.7%

VanEck Pharmaceutical ETF

Proportion10.06%

FT Vest DJIA Dogs 10 Target Income ETF

Proportion9.82%

Health Care Select Sector SPDR Fund

Proportion9.32%

Proshares Ultra Health Care

Proportion9%

iShares U.S. Healthcare ETF

Proportion8.9%

JPMorgan Healthcare Leaders ETF

Proportion8.38%

First Trust NASDAQ Pharmaceuticals ETF

Proportion8.28%

Fidelity MSCI Health Care Index ETF

Proportion7.67%

Franklin Income Focus ETF

Proportion7.08%

Dividend



A total of 46.31B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Apr 14, 2026

JNJ.NB Interim Cash Dividend of gross USD 1.34 paid on Jun 09, 2026 going ex on May 26, 2026

May 26, 2026

Jun 09, 2026

May 26, 2026

Jan 02, 2026

JNJ.NB Final Cash Dividend of gross USD 1.3 paid on Mar 10, 2026 going ex on Feb 24, 2026

Feb 24, 2026

Mar 10, 2026

Feb 24, 2026

Jan 02, 2025

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025

Feb 18, 2025

Mar 04, 2025

Feb 18, 2025

Oct 15, 2024

JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024

Nov 26, 2024

Dec 10, 2024

Nov 26, 2024

Jul 17, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024

Aug 27, 2024

Sep 10, 2024

Aug 27, 2024

Apr 16, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024

May 21, 2024

Jun 04, 2024

May 20, 2024

Jan 02, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024

Feb 20, 2024

Mar 05, 2024

Feb 16, 2024

Oct 19, 2023

JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023

Nov 21, 2023

Dec 05, 2023

Nov 20, 2023

Jul 20, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023

Aug 28, 2023

Sep 07, 2023

Aug 25, 2023

Apr 18, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023

May 23, 2023

Jun 06, 2023

May 22, 2023

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data